A perturbation of antithrombin-III and protein C coupling associates with an increase of anti-β2-glycoprotein I antibody in non-antiphospholipid antibody syndrome cerebral ischemia

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 8, 2002, Pages 703-709

  Chen, W H ^a   Kao, Y F ^a   Lan, M Y ^a   Chang, Y Y ^a   Liu, Jia Shou ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Anti 2 glycoprotein I antibody; Antithrombin; Cerebral ischemia; Protein C

Indexed keywords

ALBUMIN; AMINOTRANSFERASE; ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1 ANTIBODY; CREATININE; PROTEIN C;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; BRAIN ISCHEMIA; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBIN III; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN C; THROMBOSIS;

EID: 0036919718     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200212000-00006     Document Type: Article

References (32)

1. 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899-1906.
2. Alarcon-Segovia D, Cabral AR. The antiphospholipid/cofactor syndromes. J Rheumatol 1996; 23: 1319-1320.
3. 2-glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995; 34: 1031-1036.
4. Fiallo P, Tomasina C, Clapasson A, Cardo PP. Antibodies to beta2-glycoprotein in ischemic stroke. Cerebrovasc Dis 2000; 10: 293-297.
5. Viard JP, Amoura Z, Bach JF. Anti-beta 2-glycoprotein I antibodies and thrombosis. Clin Rev Allergy Immunol 1995; 13: 67-72.
6. Chen WH, Liu JS. An unusual increase of blood anti-beta 2-glycoprotein-I antibody but not antiphospholipid antibody in cerebral ischemia. Angiology 2001; 52: 149-154.
7. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T, et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 2001; 47: 1008-1015.
8. de Groot PG, Derksen R. The influence of antiphospholipid antibodies on the protein C pathway. In: Khamashta MA (editor): Hughes Syndrome. New York: Springer; 2001. pp. 307-316.
9. Chen WH, Chang YY, Chou MS, Liu JS. The lipoprotein profile of young adults with cerebral atherosclerosis. Southeast Asian J Trop Med Publ Health 1996; 27: 178-183.
10. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythrematosus. Arthritis Rheum 1982; 25: 1271-1277.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythrematosus [Letter]. Arthritis Rheum 1997; 40: 1725.
13. Granel F, de Maistre E, Challier B, Weber M, Weber M, Schmutz JL. Ischemic stroke in young patients and/or livedo: Is it important to look for anti-beta 2-glycoprotein I antibodies [Fre]. Rev Med Interne 1998; 19: 709-712.
14. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, et al. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: The Honolulu heart program. Stroke 2001; 32: 1701-1706.
15. Carreras LO, Forastiero RR. Pathogenic role of antiprotein-phospholipid antibodies. Haemostasis 1996; 26 (suppl 4): 340-357.
16. Hwang KK, Grossman JM, Visvanathan S, Chukwuocha RU, Woods VL Jr, Le DT, et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167: 7192-7198.
17. Arvieux J, Pernod G, Regnault V, Darnige L, Garin J. Some anticardiolipin antibodies recognize a combination of phospholipids with thrombin-modified antithrombin, complement C4b-binding protein, and lipopolysaccharide binding protein. Blood 1999; 93: 4248-4255.
18. 2-glycoprotein I antibody on factor Va degradation by activated-protein C and its cofactor protein S. Am J Hematol 1995; 49: 89-91.
19. Martinuzzo M, Forastiero R, Adamczuk Y, Cerrato G, Carreras LO. Activated protein C resistance in patients with anti-beta 2 glycoprotein I antibodies. Blood Coagul Fibrinolysis 1996; 7: 702-704.
20. 2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91: 1999-2004.
21. Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K, Koike T. β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999; 42: 167-174.
22. 2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipid. J Clin Invest 1997; 99: 2260-2268.
23. Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surface. Thromb Haemost 1998; 79: 79-86.
24. Atsumi T, Khamashta MA, Amengual O, Donohoe S, Mackie I, Ichikawa K, et al. Binding of anticardiolipin antibodies to protein C via β2-glycoprotein I: A possible mechanism in the inhibitory effect of anticardiolipin antibodies on the protein C system. Clin Exp Immunol 1998; 112: 325-333.
25. Mori T, Takeya H, Nishioka J, Gabazza E, Suzuki K. β2-glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996; 75: 49-53.
26. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated-protein-C resistance in cancer patients. Haemostasis 1997; 27: 112-118.
27. Vaziri ND, Alikhani S, Patel B, Nguyen Q, Barton CH, Gonzales EV. Increased levels of protein C activity, protein C concentration, total and free protein S in nephrotic syndrome. Nephron 1988; 49: 20-23.
28. Hooper WC, Phillips DJ, Ribeiro M, Benson J, Evatt BL. IL-6 upregulates protein S expression in the HepG-2 hepatoma cells. Thromb Haemost 1995; 73: 819-824.
29. Niessen RW, Lamping RJ, Jansen PM, Prins MH, Peters M, Taylor FBJ, et al. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997; 78: 1088-1092.
30. Esmon CT. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000; 95: 1113-1116.
31. Esmon CT. Possible involvement of cyto-kines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract Res Clin Haematol 2000; 12: 343 -359.
32. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001; 29 (suppl): S90-S94.